Search

2023 MAY 6 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Data detailed on attention deficit hyperactivity disorders have been presented. According to [...]

PRESCRIBING NOTES Narcolepsy, Shift work sleep disorder, Sleep apnea Modafinil is a selective, non-amphetamine wakefulness-promoting agent, it reduces excessive daytime sleepiness seen in narcolepsy without inducing anxiety or physical symptoms [...]

PRESCRIBING NOTES Narcolepsy, Shift work sleep disorder, Sleep apnea Modafinil is a selective non-amphetamine wakefulness-promoting agent. It reduces excessive daytime sleepiness seen in narcolepsy without inducing anxiety or physical symptoms [...]

PRESCRIBING NOTES Narcolepsy, Shift work sleep disorder, Sleep apnea Modafinil is a selective, non-amphetamine wakefulness-promoting agent. It reduces excessive daytime sleepiness seen in narcolepsy without inducing anxiety or physical symptoms [...]

PRESCRIBING NOTES Narcolepsy, Shift work sleep disorder, Sleep apnea Modafinil is a selective, non. amphetamine wakefulness-promoting agent. It reduces excessive daytime sleepiness seen in narcolepsy without inducing anxiety or physical [...]

PRESCRIBING NOTES Narcolepsy, Shift work sleep disorder, Sleep apnea Modafinil is a selective, non-amphetamine wakefulness-promoting agent. It reduces excessive daytime sleepiness seen in narcolepsy without inducing anxiety or physical symptoms [...]

PRESCRIBING NOTES Narcolepsy, Shift work sleep disorder, Sleep apnea Modafinil is a selective, non-amphetamine wakefulness-promoting agent. It reduces excessive daytime sleepiness seen in narcolepsy without inducing anxiety or physical symptoms [...]

PRESCRIBING NOTES Narcolepsy, Shift work sleep disorder, Sleep apnea Modafinil is a selective, non-amphetamine wakefulness-promoting agent. It reduces excessive daytime sleepiness seen in narcolepsy without inducing anxiety or physical symptoms [...]

PRESCRIBING NOTES Narcolepsy, Shift work sleep disorder, Sleep apnea Modafinil is a selective, non-amphetamine wakefulness-promoting agent. It reduces excessive daytime sleepiness seen in narcolepsy without inducing anxiety or physical symptoms [...]

PRESCRIBING NOTES Narcolepsy, Shift work sleep disorder, Sleep apnea Modafinil is a selective, non-amphetamine wakefulness-promoting agent. It reduces excessive daytime sleepiness seen in narcolepsy without inducing anxiety or physical symptoms [...]

PRESCRIBING NOTES Narcolepsy, Shift work sleep disorder, Sleep apnea Modafinil is a selective, non-amphetamine wakefulness-promoting agent. It reduces excessive daytime sleepiness seen in narcolepsy without inducing anxiety or physical symptoms [...]

PRESCRIBING NOTES Narcolepsy, Shift work sleep disorder, Sleep apnea Modafinil is a selective, non-amphetamine wakefulness-promoting agent. It reduces excessive daytime sleepiness seen in narcolepsy without inducing anxiety or physical symptoms [...]

* New meta-analysis challenges recommendations for MPH as first-line treatment for adult ADHD. * The methods and findings are compared with those of a previous meta-analysis. * The new meta-analysis finds smaller MPH effect sizes, no significant association between MPH mean daily dose and effect size, no advantage of observer- versus self-rated measures, lack of MPH efficacy in adults with ADHD and comorbid substance abuse, and questionable comparability of MPH efficacy between children and adults. * High-quality head-to-head trials with other treatment options are needed to assess MPH as first-line treatment for adult ADHD, the authors conclude., Results of a new meta-analysis challenge current guidelines recommending methylphenidate (MPH) as first-line treatment in adults with attention-deficit/hyperactivity disorder (ADHD). Comparing the new findings with those of a previous meta-analysis, [...]

Classification: Amphetamine. Common Usage: Lisdexamfetamine dimesylate is indicated for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children 6-12 years and in adults as an integral part of a total treatment [...]

* Other brand versions of methylphenidate include Metadate ER, Metadate CD, Methylin ER, Methylin Chewable Tablets, and Concerta. These formulations have unique prescribing information. Classification: Central nervous system stimulant. Common [...]

CLASSIFICATION: Amphetamine COMMON USAGE: Lisdexamfetamine dimesylate is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children 6-12 years and in adults (April 2008) as an integral part [...]

CLASSIFICATION: Stimulant. COMMON USAGE: Modafinil is used to improve wakefulness in patients with excessive daytime sleepiness associated with narcolepsy. Modafinil is under review for treatment of attention-deficit/hyperactivity disorder (ADHD) in [...]

The FDA has directed the manufacturers of all 15 pharmaceuticals approved for the treatment of attention deficit hyperactivity disorder (ADHD) to develop patient medication guides to alert patients, parents of [...]

Byline: MacMillan, Amanda ADHD drug danger By Amanda MacMillan About 4 million kids take prescription drugs for attention deficit hyperactivity disorder (ADHD), a number that keeps climbing. Now, two new [...]

In late October, FDA announced that pemoline will no longer be available in the United States because the risks of liver toxicity associated with the drug's use outweigh the benefits [...]

Drug: Teriparatide (Forteo) Class: Bone formation agent Manufacturer: Eli Lilly and Company Indications: Treatment of osteoporosis in postmenopausal women at high risk for a fracture. Treatment of men with primary [...]

Amphetamine/dextroamphetamine (Adderall XR) Class: CNS stimulant Manufacturer: Manufactured by Catalytica Pharmaceuticals, Inc; marketed by Shire US, Inc Indication: Treatment of attention-deficit hyperactivity disorder Dosage: In children 6 years or older, [...]

Across the continent, young killers prove to be graduates of Ritalin therapy Every day in North America millions of children are chemically lobotomized. diagnosed as suffering from attention deficit disorder [...]

PRESCRIBING NOTES Narcolepsy, Shift work sleep disorder. Sleep apnea Modafinil is a selective, non-amphetamine wakefulness-promoting agent. It reduces excessive daytime sleepiness seen in narcolepsy without inducing anxiety or physical symptoms [...]

GAITHERSBURG, MD. -- A Food and Drug Administration advisory committee declared that modafinil is not safe for treating ADHD in children and adolescents by a 12-1 vote, although committee members [...]

A randomized, double-blind placebo controlled trial investigated the efficacy and tolerability of atomoxetine (Strattera) for treating attention-deficit/hyperactivity disorder and comorbid anxiety disorder in adults. There is little in the literature [...]

The Food and Drug Administration has sent letters to all manufacturers of medications approved for treating attention-deficit hyperactivity disorder, instructing them to develop patient medication guides within 30 days to [...]

A dverse events were well tolerated in a majority of 3- to 5-year-olds who took methylphenidate for attention-deficit hyperactivity disorder, based on data from 183 children, said Tim Wigal, Ph.D., [...]

Company: Shire CII Pharmacologic class: CNS stimulant Active ingredient: Methylphenidate 10mg, 15mg, 20mg, 30mg; delivered over 9 hours: transdermal patches. Indication: Attention deficit hyperactivity disorder (ADHD). Pharmacology: Daytrana is a [...]

An FDA advisory committee has recommended that drugs used to treat attention-deficit hyperactivity disorder (ADHD), both methylphenidates and amphetamines, should carry a 'black box' warning about an increased risk of [...]

BOCA RATON, FLA. -- Children and adolescents with attention-deficit hyperactivity disorder did not experience withdrawal or discontinuation syndrome after abrupt cessation of modafinil film-coated tablets in a phase III, double-blind, [...]

Adderall XR (controlled-release amphetamine), used to treat patients with attention deficit hyperactivity disorder, has been withdrawn from the Canadian market, based on American postmarketing reports of sudden deaths in pediatric [...]

HONOLULU -- Growth reductions seen in a 2-year study of 44 children taking mixed amphetamine salts for attention-deficit hyperactivity disorder spotlight the need to monitor height and weight, Dr. Peter [...]